Alirocumab shows promise while treatment to reduce LDL-cholesterol in Stage III study A recently published clinical trial statement reviewing the first completed Stage III study in the ODYSSEY development program has shown that alirocumab showed significantly better LDL-C lowering than ezetimibe, with a comparable safety profile to ezetimibe http://www.synmcg.com/headache.html . The record, in the January problem of Future Cardiology which is published, provides a comprehensive summary of the ODYSSEY MONO trial, including detail on the scholarly study design, data analysis, discussion and outcomes on the implications of the findings, authored by lead investigator of the trial Eli M Roth.
We appreciate the initiatives that Teva has made to day and are looking towards continuing to build the ADASUVE brand,’ stated Thomas B. King, Alexza President and CEO. ‘We remain confident in ADASUVE's long-term commercial program and prospects to work with Teva to effect a soft transition. It is our intention to work diligently in 2016 to identify a new U.S. Industrial partner for ADASUVE.’.. Alexza programs to reacquire U.S. Privileges for ADASUVE inhalation powder from Teva Alexza Pharmaceuticals, Inc. announced today that it programs to reacquire the U.S., a subsidiary of Teva Pharmaceutical Industries Ltd., with around target completion date of January 1, 2016. Teva and Alexza also intend to restructure the obligations beneath the outstanding notice from Teva. Alexza and Teva will work on a transition agreement to keep product availability to sufferers and health care providers after the come back of the rights to Alexza.